Trials aiming for glycemic equipoise should appraise the long-term effects of GLP-1 RAs on coronary events independent of glycemic control
The FDA has restricted compounding pharmacies from producing BPC-157 due to safety concerns, and the World Anti-Doping Agency classifies it as an S0 Unapproved Substance. Manufacturing and distribution are largely underground, raising quality control concerns for black-market products
[DOI] [PubMed] [Google Scholar] 20
GLP-1 (glucagon-like peptide-1) agonists, such as semaglutide and tirzepatide, have gained significant attention for their effectiveness in promoting weight loss
Patients should follow a systematic rotation pattern and maintain a written log to track application sites and prevent skin complications
Probiotics, by contrast, would theoretically work by modestly influencing the body's own GLP-1 productiona far less direct and potentially much weaker effect